HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock.

AbstractOBJECTIVE:
The aim of this study was to review the incidence and type of central venous catheter-related bloodstream infection in children on treatment with home parenteral nutrition (PN) before and after the introduction of taurolidine. Taurolidine is a catheter lock solution that prevents biofilm formation and has broad-spectrum bactericidal and antifungal action. Its use in pediatric patients on PN has only been reported in case studies.
METHODS:
A total of 19 children were reviewed, with the diagnoses of enteropathy (8 cases), short bowel syndrome (7 cases), and gastrointestinal dysmotility (4 cases). Incidence and type of sepsis were reviewed for 8 to 12 months pre- (when heparin was used) and 2 to 33 months postintroduction of the taurolidine catheter lock.
RESULTS:
There were 8.6 episodes of catheter-related bloodstream infections per 1000 catheter days with heparin and 1.1 episodes per 1000 catheter days with taurolidine (P=0.002). A total of 14 of the 19 patients (74%) had no infections for up to 33 months after changing to taurolidine. No reports of multiresistant organisms or adverse effects with taurolidine were found.
CONCLUSIONS:
Taurolidine line lock was associated with a decreased incidence of catheter-related bloodstream infections. This finding supports its use in patients with a history of septicemia on treatment with cyclical PN.
AuthorsHui-Ping Chu, Joanne Brind, Rajeev Tomar, Susan Hill
JournalJournal of pediatric gastroenterology and nutrition (J Pediatr Gastroenterol Nutr) Vol. 55 Issue 4 Pg. 403-7 (Oct 2012) ISSN: 1536-4801 [Electronic] United States
PMID22595973 (Publication Type: Journal Article)
Chemical References
  • Anti-Infective Agents
  • Anticoagulants
  • Thiadiazines
  • Taurine
  • taurolidine
  • Heparin
Topics
  • Adolescent
  • Adult
  • Anti-Infective Agents (therapeutic use)
  • Anticoagulants (therapeutic use)
  • Catheter-Related Infections (blood, prevention & control)
  • Catheterization, Central Venous (adverse effects)
  • Central Venous Catheters (adverse effects)
  • Child
  • Child, Preschool
  • Gastrointestinal Diseases (therapy)
  • Gastrointestinal Motility
  • Heparin (therapeutic use)
  • Humans
  • Infant
  • Infant, Newborn
  • Parenteral Nutrition, Home (adverse effects)
  • Sepsis (blood, etiology, prevention & control)
  • Short Bowel Syndrome (therapy)
  • Taurine (analogs & derivatives, therapeutic use)
  • Thiadiazines (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: